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Abstract
Aims: The demographics, ethnicity, symptoms, lifestyle characteristics, and treatment outcomes are analyzed in
participants of a study designed to evaluate uterine leiomyoma growth and correlate symptoms and outcomes in
a clinically relevant population of women (Fibroid Growth Study).
Methods: Women included in the Fibroid Growth Study (FGS) completed a medical history and physical
examination, underwent T1-weighted and T2-weighted magnetic resonance image (MRI) scans, provided urine
and blood samples at each scheduled MRI, and responded to an initial extensive telephone-administered
questionnaire followed by abbreviated monthly questionnaire updates. Summary scores were developed to
quantify stress, pain, and bleeding. The Wilcoxin test was used for statistical comparisons between study
participant characteristics and tumor-related characteristics.
Results: Participants included 116 premenopausal women, ranging in age from 20 to 54 years; 48% were black
women, 41% were white women, 10% were women of other or multiple racial backgrounds, and 1% did not self-
identify. Over 90% of participants had multiple leiomyomas, and nearly a third had more than 10. Black women
were younger and had more fibroids, but no differences were found in the proportions of black and white women
choosing an intervention; 44% of black women and 40% of white women chose intervention during the study.
Conclusions: There was no correlation between number of leiomyomas or uterine size and choosing treatment.
However, women who opted for treatment were more symptomatic, with higher bleeding and pain scores,
compared with the women with no intervention. Consequently, our study suggests that once women are
symptomatic, black and white women choose surgery as a treatment method for the same reasons and at about
the same rates. Moreover, our data suggest that bleeding and pain, not the size or multiplicity of fibroids,
determine the choice for intervention. Therefore, aggressive management of pain and bleeding may be effective
in reducing the need for surgical intervention.
Introduction
Uterine leiomyomas (fibroids) are the most commonreproductive tract tumor in women and a significant
health concern in premenopausal women.1 Although the tu-
mors are not malignant, they are the leading cause for hys-
terectomy in the United States.2,3 Leiomyoma-related
healthcare accounted for about 320 thousand hospital proce-
dures and an estimated total direct cost of more than 2 billion
dollars per year, primarily related to hysterectomy costs.2
Previous studies found that among women with leiomyomas
and uterine size of 8 weeks gestational age, about 20% had
hysterectomies within a year.4 Among newly diagnosed cases
of uterine fibroids in the Nurses’ Health Study, about 15% had
hysterectomy within 21 months.5 In a more general popula-
tion of women diagnosed with leiomyomas, only about one
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third had surgery within 5 years.6 Factors possibly associated
with increased likelihood of hysterectomy included large
uterine size, excessive bleeding, and prior surgery for pelvic
adhesions or gallbladder removal.
Black women are at a particularly high risk for developing
fibroids. Ultrasound screening for leiomyomas in randomly
selected members of a large urban healthcare plan estimated
that black women had over an 80% cumulative incidence of
leiomyomas by age 50, and white women had nearly a 70%
cumulative incidence of leiomyomas by the same age.7 A
number of studies have shown that black women have leio-
myomas at younger ages and have more hysterectomies and
myomectomies at earlier ages than white women.3,5,7
Women typically have more than one leiomyoma, which
may or may not cause similar problems or grow at similar
rates, complicating conclusions about tumor characteristics
and clinical outcomes. Most leiomyomas grow slowly and
remain asymptomatic for prolonged periods. However, an-
ecdotal reports suggest that individual leiomyomas may un-
dergo episodes of rapid growth and become clinically
symptomatic in a short time period. Fast-growing, large
leiomyomas appear to be the most problematic. Given that
70%–80% of women have leiomyomas but not all are symp-
tomatic, a clinically relevant question is: What causes leio-
myomas to grow and cause symptoms?
The Fibroid Growth Study (FGS) was designed to investi-
gate the growth dynamics of uterine leiomyomas over time
and correlate symptoms and outcomes in a clinically relevant
population of women. A clinically relevant population was
defined as premenopausal women with preexisting large fi-
broids (initially as 5 cm diameter and a uterus enlarged to
the size of gestational week 12 of pregnancy), predicting that
this population of women would likely have symptoms as-
sociated with fibroids and be more likely to choose a thera-
peutic intervention. Because surgical intervention is the most
common treatment for uterine leiomyomas, we anticipated
that about one third of the women enrolled in the study would
elect to have either a hysterectomy or a myomectomy. Con-
sequently, we planned to follow participants for 1 year or
until surgery (myomectomy or hysterectomy). Although the
selection criteria were set to recruit women with large tumors
and clinical symptoms, surgery was not a requirement for
study inclusion. The ability to have magnetic resonance im-
aging (MRI) data over a 1-year period for women who did not
have surgery was considered highly important and informa-
tive. Another important aspect of the study was to investigate
leiomyoma growth in women of minority populations. The
goal of recruitment was to ensure that half of the study pop-
ulation represented the minority population most affected by
the condition (i.e., black women).
This paper presents the participant demographics, lifestyle,
and symptoms related to fibroids and our analysis of the
determinants for choosing therapeutic intervention during
the course of the study.
Materials and Methods
The FGS was conducted at the General Clinical Research
Center (GCRC) at University of North Carolina (UNC) Med-
ical Center, Chapel Hill, and approved by the human subjects
review boards at the National Institute of Environmental
Health Sciences (NIEHS) and UNC. The inclusion criteria for
participant enrollment were (1) age >18 years, (2) premeno-
pausal, (3) not currently pregnant, (4) willing and able to have
(MR) (weight<350 pounds, waist<52 inches, and no IUD) at
the UNC Medical Center, (4) not on gonadotropin-releasing
hormone (GnRH) therapy, and (5) ultrasound-confirmed di-
agnosis of leiomyomas of 5 cm in diameter and a uterus
enlarged to the size of gestational week 12 of pregnancy. To
obtain fibroids of smaller sizes for the growth analysis com-
ponent of the study, the size criterion was amended in the last
few months of the study to include women with leiomyomas
2 cm in diameter and at least an 8-week gestational uterus
size. The 4 women enrolled with this smaller size criterion
were included in this analysis to represent the entire popu-
lation of women enrolled in the FGS. After enrollment and
informed consent, MRI scans were conducted at the first visit
and then conducted approximately 3, 6, and 12 months later.
Women were asked to bring all current medications for re-
cording. If a participant chose one of the major treatment
options for fibroid-related problems (embolization or sur-
gery) and the last MRI took place>2 months prior, the patient
was scheduled for a presurgery MRI. Participants having
myomectomy had the option to remain in the study post-
surgery; participants who had hysterectomy or embolization
were not followed posttreatment. During each scheduled MRI
visit, participants underwent a pelvic examination, provided
urine and blood samples, and responded to interview ques-
tions about medical history (initial visit) and medication use
(initial visit) Data on demographics, lifestyle factors, and
symptoms were collected with an initial telephone interview.
The symptom data were updated with monthly telephone
interviews. Women who elected surgery were contacted with
a follow-up telephone-administered questionnaire to assess
reasons for surgery.
Study recruitment
Because the study was based at the UNC Medical Center,
most participants were recruited through the physician net-
work within the UNC Hospitals’ system. The majority were
referred from the obstetrics=gynecology ultrasound clinic.
Family practice physicians in the network received brochures,
and a grand rounds presentation described the study. Addi-
tional recruitment came from women responding to the
website, word of mouth, press releases, public service an-
nouncements on the radio, and informational study book-
marks placed at area libraries.
Symptom monitoring
During the initial enrollment interview, women were asked
about their general health, current symptom status, stress,
pelvic pain and discomfort, and vaginal bleeding. The ques-
tions about stress, pelvic pain, and bleeding were also asked at
each subsequent monthly telephone interview. A stress index
was calculated by combining answers to eight questions
about economic difficulties, time pressures, experiencing ‘‘too
much to handle,’’ and the impact of this stress on sleep and
daily life. Each question had four choices rated from 0 to 3
(low to high stress). These values were summed for all eight
questions to yield a score ranging from 0 to 24. The score was
then multiplied by 100=24 to convert it to a 100-point scale.
Similarly, a pain score was calculated by combining answers
from two questions assessing the amount of pain or discom-
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fort, with four choices rated 0–3; two questions were about
number of days experiencing pain (rated 0–8) or discomfort
(rated 0–4), and one question was about days stayed home
because of pain (rated 0–6). A scale was also developed to
assess whether bleeding was a problem (perceived bleeding
problem scale), including whether vaginal bleeding limited
daily responsibilities or social activities. Finally, a 100-point
amount-of-bleeding scale was developed based on number of
days of bleeding, number of days of spotting, pad=tampon
use on heavy bleeding days, gushing-type bleeding, clots,
needing extra means of protection beyond pads and tampons,
and frequency of menses. As validation, we evaluated the
correlation between the amount-of-bleeding score and he-
matocrit or hemoglobin levels. The specific questions used for
all the symptom scales can be found in the enrollment ques-
tionnaire (www.niehs.nih.gov=fibroids=home).
Statistical analysis
Statistical tests included Wilcoxin test and two-sided
Mann-Whitney to compare participant and tumor-related
variables, except for the hormone use variable, which was
tested with the chi-square test. Spearman correlation was
used for associations among bleeding scores, hematocrit level,
and hemoglobin level.
Results
Of 151 women initially evaluated in the study, 116 women
met all requirements and completed at least one MRI. Women
were excluded because they began taking lupron (n¼ 1) or
were not eligible based on review of the first MRI (n¼ 4).
Participants withdrew because they were planning pregnancy
or because of other study-related concerns, such as claustro-
phobia or scheduling difficulties (n¼ 22). Only 8 women
dropped out or were excluded because of noncompliance
(4 African Americans, 2 white women, and 2 women of other
heritage). Among the 116 participants included in the study,
30 women opted for treatment after one MRI, 8 women opted
for treatment after their second MRI, 4 had treatment after
their third MRI, and 6 women had treatment after their fourth
MRI while still in the study. The study ended before 25 wo-
men completed a fourth MRI. Women who had a hystero-
scopic resection or a myomectomy before completing the
study (n¼ 22) were invited to continue in the study after
treatment; 20 completed further monthly questionnaires, and
17 completed additional MRIs, as well.
Characteristics of study participants
The demographic and lifestyle characteristics of the 116
participants in the FGS are shown in Table 1. Nearly half self-
identified as African American=black or black with other
heritage (subsequently referred to as black participants), 48
self-identified as white=Caucasian (subsequently referred to
as white participants), and 11 were of other heritages. Most
participants were college educated and employed and had
health insurance. Fewer black participants had postbacca-
laureate degrees and high household incomes compared with
white participants. Black participants were also slightly
younger ( p¼ 0.037) compared with white participants. The
average age for black participants was 38 years and for whites
was 40 years.
Fibroid and symptom characteristics of the participants are
shown in Table 2. Over 90% of participants had multiple
leiomyomas, with nearly a third having more than 10. Black
participants had slightly more leiomyomas than white par-
ticipants ( p¼ 0.04). Most participants were first diagnosed
with leiomyomas within the last 5 years. Ten had prior
Table 1. Characteristics of Participants in Fibroid












<30 9 (8) 4 (7) 4 (8)
30–34 24 (21) 16 (29) 8 (17)
35–39 23 (20) 12 (22) 6 (12)
40–44 33 (28) 16 (29) 13 (27)
45þ 27 (23) 7 (13) 17 (35)
p¼ 0.372
Educationb
High school 26 (23) 14 (25) 6 (12)
College 42 (37) 22 (40) 17 (35)
Postbaccalaureate
degree
47 (41) 19 (35) 25 (52)
Missing 1
Household incomec
<$40,000 19 (17) 11 (22) 5 (11)
$40,000–59,999 26 (24) 14 (27) 11 (23)
$60,000–99,999 48 (44) 27 (47) 18 (38)
$100,000 17 (15) 2 (4) 13 (28)
Missing 6 4 2
Employed
No 19 (17) 10 (18) 8 (17)
Part-time
(<37 hours=week)
19 (17) 9 (16) 7 (15)




Yes 55 (48) 22 (41) 28 (58)
No 59 (52) 32 (59) 20 (42)
Missing 2 1
Health insurance
Yes 107 (95) 53 (95) 46 (96)
No 6 (5) 3 (5) 2 (4)
Missing 3 1
BMI
<25 43 (37) 16 (29) 23 (48)
25–29 37 (32) 20 (36) 12 (25)
30–34 17 (15) 8 (15) 8 (17)
35þ 19 (16) 11 (20) 5 (10)
Smoking
Never 83 (73) 41 (75) 34 (71)
Past 22 (19) 8 (15) 11 (23)
Current 9 (8) 6 (11) 3 (6)
Missing 2
aTotal sample includes 11 participants in the Other category for
ethnicity.
bHigh school includes those with some training beyond high
school but no college degree; college degree includes those with
some postbaccalaureate education but no further degree.
cHousehold income is adjusted for number of people in household
and indexed to a household of two.
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Time since initial diagnosis of fibroids (years)
<1 33 (29) 14 (25) 17 (37)
1–2 26 (23) 14 (25) 9 (20)
3–5 19 (17) 9 (16) 8 (17)
5–9 19 (17) 11 (20) 7 (15)
10þ 15 (13) 8 (14) 5 (11)
Missing 4 1 2
p¼ 0.21b
Uterine volume (cm3)c
<100 9 (8) 3 (5) 6 (12)
100–249 47 (41) 24 () 19 (40)
250–499 23 (20) 12 (21) 9 (19)
500–999 23 (20) 11 (19) 8 (17)
1000þ 14 (12) 7 (12) 6 (12)
p¼ 0.31
Number of fibroidsd
1 9 (8) 2 (4) 5 (10)
2 14 (12) 6 (11) 8 (17)
3–5 23 (20) 11 (19) 10 (21)
6–10 35 (30) 19 (33) 12 (25)
>10 35 (30) 19 (33) 13 (27)
p¼ 0.04
General health
Excellent to very good 62 (54) 28 (49) 27 (56)
Good 43 (38) 22 (39) 19 (40)
Fair 9 (8) 6 (11) 2 (4)




None 86 (74) 51 (75) 35 (73)
Oral contraceptives for contraception 11 (9) 7 (10) 4 (8)
Oral contraceptives for irregular period or symptoms 13 (11) 5 (7) 8 (17)
Other hormone 5 (4) 4 (7) 1 (2)
Missing 1
p¼ 0.30
Tolerance of current symptoms
Satisfied 48 (42) 19 (33) 23 (48)
Mixed feelings 31 (27) 18 (32) 11 (23)
Dissatisfied 19 (17) 10 (18) 8 (17)




Mean 32.2 36.0 29.1
SD 17.6 20.1 13.8




Mean 31.9 33.6 30.0
SD 25.1 24.2 25.0
Range 0–100 0–83 0–88
Missing 3 1 1
p¼ 0.50
Bleeding-problem scale
Mean 32.9 37.5 27.3
SD 30.4 31.4 28.1
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surgery for leiomyomas (5 women had myomectomies, 5
women had hysteroscopic resections). Two women enrolled
in the study within 1 year of their last surgery, 6 women
enrolled within 1–5 years, and 2 women enrolled > 5 years
after their last surgery. Although black participants had
slightly more leiomyomas than white participants, symptom
scores were similar between black and white participants
(Table 2). About 90% of both black and white participants
considered themselves to be in good to excellent health, but
less than half were satisfied with their current symptom sta-
tus. No differences were found between black and white
participants having treatment or in their symptoms, including
pain or bleeding. Of the 48 participants who had surgical or
embolization treatment, 25 (44%) were black and 19 (40%)
were white (Table 2). The most common intervention was
myomectomy.
Comparisons of participants who opted for therapeutic
intervention
Because no differences were found between blacks and
whites in having treatment or in symptoms, we combined
ethnicities in comparing those who chose intervention and
those who did not choose intervention (Table 3). Time since
first diagnosis of leiomyomas, uterine size, and number of
leiomyomas were similar for the 48 participants who opted
for intervention (hormonal, surgical, or others combined)
compared with the 68 participants who did not choose in-
tervention (Table 3). Stress scale scores were also similar for
women opting for treatment and women not opting for
treatment. However, participants choosing treatment were
more concerned with their symptoms ( p< 0.01) and had
higher scores on pain ( p¼ 0.02). Participants choosing treat-
ment also had higher bleeding scores ( p< 0.001) compared
with women who did not choose treatment (Table 3). More-
over, scores for perceived bleeding and amount of bleeding
increased over time with respect to first diagnosis ( p¼ 0.013
and p¼ 0.029, respectively). The accuracy of the bleeding
scores was supported by the strong overall (all races com-
bined) correlation found between the amount of bleeding
reported and clinical measurements of hematocrit and he-
moglobin. Specifically, the correlation between the amount of
bleeding and hematocrit was 0.2427 ( p¼ 0.0096) and
0.2995 for amount of bleeding and hemoglobin ( p¼ 0.0013).
The overall mean hematocrit values for treated and un-
treated participants were 36.6875 (SE 0.4972) and 37.202
(SE 0.3752), respectively, and mean hemoglobin values
were 12.3583 (SE 0.2125) and 12.5662 (SE 0.1586), respec-
tively.
Twenty participants opting for surgery were followed for
an average of 7.5 months (0.8) after surgery. The 20 women
followed after treatment showed similar pretreatment scores
on the symptom scales as at the initial interview, but their
scores decreased markedly after treatment (Fig. 1).
Discussion
We sought to understand the characteristics of premeno-
pausal women with large fibroids and the factors underlying
a choice for therapeutic intervention. Rigorous review of the
data from 151 women who initially enrolled in the FGS de-
termined that 116 participants met all criteria for inclusion
into the study analysis. Of the 116 participants included in this
present analysis, 48 participants opted for intervention. We
found that the primary determinants for seeking treatment
were pain and bleeding. Importantly, we validated the self-
reported bleeding data by comparing clinical measurements
of hematocrit and hemoglobin to find highly significant re-
lationships. Other physical factors, including time since initial










Mean 18.4 17.9 18.5
SD 14.8 13.8 15.9
Range 0–56 0–56 0–51
Missing 3 1 1
p¼ 0.94
Treatment
None 68 (59) 32 (56) 29 (60)
GnRH agonist in preparation for surgery 7 2 3
Hysteroscopic resection 4 1 3
Embolization 2 1 1
Myomectomy 20 12 7
Hysterectomy 15 9 5
Missing 0
p¼ 0.58
aTotal sample includes 11 participants in the Other category for ethnicity.
bp values are based on comparing the entire distribution of the variables in African Americans and whites using the nonparametric
Wilcoxon rank sum test, except for the hormone use and treatment variables, which were tested with the chi-square test.
cUterine volume was calculated from ultrasound data on uterine length, width, and AP diameter using the ellipsoid formula
(0.52LWAP); when ultrasound uterine diameters were not available, the uterine volume was determined based on the pelvic
examination estimated weeks of gestation.
dNumber of fibroids was assessed by counting fibroids observable on the first visit MRI. In the few cases when first visit MRI were of poor
quality because the patient moved, the count was made on the second visit MRI.
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between FGS participants choosing treatment and those who
did not. A previous study found that bleeding symptoms
were associated with greater odds of having a hysterectomy.6
Weber et al. also reported an interaction between age and
uterine size with greater odds of hysterectomy, an interaction
that we did not find in our study. The difference may be a
reflection of the selected population in the FGS, as well as the
inclusion of other treatments (embolization, myomectomy) in
addition to hysterectomy. We also found a significant differ-
ence in the tolerance of symptoms between FGS participants
choosing treatment and those who did not; however, no dif-
ferences were found between these two groups in perceived
Table 3. Fibroid and Symptom Characteristics for Treated and Untreated Participants










Age Tolerance of current symptoms
<30 5 (7) 4 (8) Satisfied 34 (50) 14 (30)
30–34 14 (21) 10 (21) Mixed feelings 20 (29) 11 (23)
35–39 9 (13) 14 (29) Dissatisfied 10 (15) 9 (19)
40–44 18 (26) 15 (21) Very dissatisfied 4 (6) 13 (28)
45þ 22 (32) 5 (10) Missing 0 1
p¼ 0.12 p< 0.01
Time since initial diagnosis of fibroids (years) Stress scale
<1 21 (32) 12 (26) Mean 31.4 33.3
1–2 16 (25) 10 (21) SD 17.0 18.6
3–5 9 (14) 10 (21) Range 4–67 0–75
5–9 10 (15) 9 (19) Missing 0 0
10þ 9 (14) 6 (13) p¼ 0.68
Missing 4
p¼ 0.65
Uterine volume (cm3)b Pain scale
<100 5 (7) 4 (8) Mean 27.0 38.7
100–299 30 (44) 17 (35) SD 23.4 25.9
300–499 14 (21) 9 (19) Range 0–100 0–87.5
500–999 12 (18) 11 (23) Missing 2 1
1000þ 7 (10) 7 (15) p¼ 0.02
p¼ 0.42
Number of fibroidsc Bleeding-problem scale
1 5 (7) 4 (8) Mean 23.7 46.6
2 9 (13) 5 (10) SD 24.1 33.8
3–5 15 (22) 8 (17) Range 0–100 0–100
6–10 20 (29) 15 (31) Missing 0 2
>10 19 (28) 16 (33) p< 0.001
p¼ 0.58
Hormone use Amount-of-bleeding scale
None 51 (75) 35 (74) Mean 14.6 23.7
Oral contraceptives
for contraception









8 (12) 5 (11) Missing 2 2
p< 0.01




Excellent to very good 38 (56) 24 (51)
Good 24 (35) 19 (40)
Fair 6 (9) 3 (6)
Poor 0 1 (2)
Missing 0 1
p¼ 0.65
ap values are based on comparing the entire distribution of the variables in treated and not treated participants with the nonparametric
Wilcoxon rank sum test except for the hormone use variable, which was tested with the chi-square test.
bUterine volume was calculated from ultrasound data on uterine length, width, and AP diameter using the ellipsoid formula
(0.52lwAP), and when ultrasound uterine diameters were not available, the uterine volume was determined based on the pelvic
examination estimated weeks of gestation.
cNumber of fibroids was assessed by counting fibroids observable on the first visit MRI. In the few cases when first visit MRI were of poor
quality because the patient moved, the count was made on the second visit MRI.
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stress levels or assessment of their general health. Based on
analysis of the extensive questionnaires participants com-
pleted at each visit and during monthly telephone interviews,
the main symptoms experienced by these FGS participants
included dissatisfaction with general health, discomfort, pain,
and bleeding.
Another important aspect of the study was to investigate
leiomyoma growth in women of minority populations. The
goal of recruitment was to ensure that half of the study pop-
ulation represented the minority population most affected
by the condition (i.e., black women). Indeed, about half (49%)
of the participants were black, 9% identified as other or
multiple racial backgrounds, and 41% were white. The suc-
cess of recruitment was largely attributed to the general
characteristics of the patient population at UNC Hospitals’
system. Secondary methods of recruitment were initiated to
maintain diversity. These included distributions of brochures
to local obstetrics=gynecology and family practices and
placing of informational study bookmarks at area libraries
and of press releases and public service announcements on
the radio.
Previous studies have shown that African American wo-
men have leiomyomas at younger ages, have more leiomyo-
mas, and have more hysterectomies and myomectomies than
do white women.5 In our study, black participants were
younger and had more leiomyomas compared with white
participants. However, we found no differences in symptom
scores or surgery rates between black and white participants.
This apparent difference between our study population and
other reports is likely a result of our emphasis on recruiting
women who had larger leiomyomas and who were more
likely to be symptomatic. Consequently, our data suggest that
once women are symptomatic, black and white women
choose surgery as a treatment method for the same reasons
and at about the same rates. Moreover, our data suggest that
bleeding and pain, not the size or multiplicity of fibroids,
determine the choice for intervention. Therefore, aggressive
management of pain and bleeding may be effective in re-
ducing the need for surgical intervention in both black and
white women.
In summary, of the 116 premenopausal women who com-
pleted requirements for the FGS, about half self-identified as
either black or white, most had multiple leiomyomas (about
one third had > 10 tumors), and most were in good to ex-
cellent health, college educated, employed with health in-
surance, had a BMI >25, were never smokers, and were not
using hormones. Black participants were slightly younger and
had slightly more leiomyomas than white participants, but
similar numbers of black and white participants opted for
treatment of uterine leiomyoma. Myomectomy was the most
common intervention, and the primary reason for treatment
was pain and bleeding.
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FIG. 1. Comparisons of clinical symptoms in FGS participants before and after treatment. Symptom scales were calculated
by summing assigned values to specific questionnaire responses and converting the sums to a 100-point scale. Stress, pain,
bleeding problems, and amount of bleeding were identified as significant factors related to treatment in the overall FGS
population. These symptoms are further compared prior to and after treatment in the subset of participants (n¼ 20) who had
treatment and were available for a follow-up questionnaire after treatment.
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